Q-omics provides the consensus-scored PHBP11 profile across patient tissues and cancer cell-line models. PHBP11 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PHBP11 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, PHBP11 RNA expression shows 7,882 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CHOL, LUAD, and LSCC as cancer lineages where PHBP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP11 survival associations across molecular data types. PHBP11 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP11 RNA expression–survival associations across cancer types. High PHBP11 expression shows unfavorable associations in CHOL, MESO, OV, READ, UCS and KIRC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for PHBP11 RNA expression.
This table summarizes PHBP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP11 shows lower tumor expression in HNSC and higher tumor expression in LUAD, LIHC, BRCA, COAD and LUSC. The LUAD box plot shows higher PHBP11 RNA expression in tumor versus normal tissue (log2 FC = +0.114, t-test p < 0.001).
This table shows molecular features associated with PHBP11 in patient tissues and cancer cell lines. In patient samples, PHBP11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
